Hypophosphatemia is defined as a phosphate level of less than 2.5 mg/dL (0.8 mmol/L). Phosphate is critical for an incredible array of cellular processes. It is one of the major components of the skeleton, providing mineral strength to bone. Phosphate is an integral component of the nucleic acids that comprise DNA and RNA. Phosphate bonds of ATP carry the energy required for all cellular functions. It also functions as a buffer in bone, serum, and urine.

The addition and deletion of phosphate groups to enzymes and proteins are common mechanisms for the regulation of their activity. In view of the sheer breadth of influence of this mineral, the fact that phosphate homeostasis is a highly regulated process is not surprising.

Phosphate in the body

The bulk of total body phosphate resides in bone as part of the mineralized extracellular matrix. This phosphate pool is accessible, although in a somewhat limited fashion. Approximately 300 mg of phosphate per day enters and exits bone tissue. Excessive losses or failure to add phosphate to bone leads to osteomalacia.

Phosphate is a predominantly intracellular anion with a concentration of approximately 100 mmol/L, although determination of the precise intracellular concentration has been difficult. Most intracellular phosphate is either complexed or bound to proteins and lipids. In response to kinases and phosphatases, these phosphate ions attach and detach from different molecules, forming a constantly shifting pool. Intracellular phosphate is essential for most, if not all, cellular processes; however, because the intracellular concentration of phosphate is greater than the extracellular concentration, phosphate entry into cells requires a facilitated transport process.

Several sodium-coupled transport proteins have been identified that enable intracellular uptake of phosphate by taking advantage of the steep extracellular-to-intracellular sodium gradient. Type 1 sodium phosphate cotransporters are expressed predominantly in kidney cells on the apical membranes of proximal tubule cells and, possibly, the distal tubule cells. They are capable of transporting organic ions and stimulating chloride conductance in addition to phosphate. Their role in phosphate homeostasis is not clear. Other sites of expression include the liver and brain.

Type 2 sodium phosphate cotransporters are expressed in the kidneys, bones, and intestines. In epithelial cells, these transporters are responsible for transepithelial transport, ie, absorption of phosphate from intestine and reabsorption of phosphate from renal tubular fluid. Type 2a transporters are expressed in the apical membranes of kidney proximal tubules, are very specific for phosphate, and are regulated by several physiologic mediators of phosphate homeostasis, such as parathyroid hormone (PTH), dopamine, and dietary phosphate. Currently, these transporters are believed to be most critical for maintenance of renal phosphate homeostasis. Impaired expression or function of these transporters is associated with nephrolithiasis.[1, 2]

Type 2b transporters are very similar, but not identical, to type 2a transporters. They are expressed in the small intestine and are also up-regulated under conditions of dietary phosphate deprivation. Type 2c transporters, initially described as growth-related phosphate transporters, are a third member of the type 2 sodium phosphate cotransporter family. They are expressed exclusively on the S1 segment of the proximal tubule and together with Type 2a transporters are essential for normal phosphate homeostasis.[3] Similarly to type 2a transporters, type 2c transporters are also regulated by diet and PTH. Loss of type 2c function results in hereditary hypophosphatemic rickets with hypercalciuria.[4]

Type 3 transporters were initially identified as viral transport proteins. Almost all cells express type 3 sodium phosphate cotransporters; therefore, these transporters presumably play a housekeeping role in ensuring adequate phosphate for all cells. The factors that regulate the activity of these transporter proteins are not completely understood. Evidence suggests, however, that these transporters also participate in the regulation of renal and intestinal transepithelial transport[5, 6] and in the regulation of bone mineralization.[7]

Circulating phosphate exists as either the univalent or divalent hydrogenated species. Because the ionization constant of acid (pK) of phosphate is 6.8, at the normal ambient serum pH of 7.4 the univalent species is 4 times as prevalent as the divalent species. Serum phosphate concentration varies with age, time of day, fasting state, and season. Serum phosphate concentration is higher in children than adults; the reference range is 4-7 mg/dL in children compared with 3-4.5 mg/dL in adults. A diurnal variation exists, with the highest phosphate level occurring near noon.

Serum phosphate concentration is regulated by diet, hormones, and physical factors such as pH, as discussed in the next section. Importantly, because phosphate enters and exits cells under several influences, the serum concentration of phosphate may not reflect true phosphate stores. Often, persons with alcoholism who have severely deficient phosphate stores may present for medical treatment with a normal serum phosphate concentration. Only after refeeding will serum phosphate levels decline, often abruptly plummeting to dangerously low levels.

Phosphate homeostasis

Phosphate is plentiful in the diet. A normal diet provides approximately 1000 mg of phosphate, two thirds of which is absorbed, predominantly in the proximal small intestine. The absorption of phosphate can be increased by increasing vitamin D intake and by ingesting a very low–phosphate diet. Under these conditions, the intestine expresses sodium-coupled phosphate transporters to enhance phosphate uptake.

Regulation of intestinal phosphate transport overall is poorly understood. Although studies had suggested that the majority of small intestine phosphate uptake is accomplished through sodium-independent, unregulated pathways, subsequent investigations have suggested that regulated, sodium-dependent mechanisms may play a greater role in overall intestinal phosphate handling than was previously appreciated. Furthermore, intestinal cells may have a role in renal phosphate handling through elaboration of circulating phosphaturic substances in response to sensing a phosphate load.[8]

Absorption of phosphate can be blocked by commonly used over-the-counter aluminum-, calcium-, and magnesium-containing antacids. Mild-to-moderate use of such phosphate binders generally poses no threat to phosphate homeostasis because dietary ingestion greatly exceeds body needs. However, very heavy use of these antacids can cause significant phosphate deficits. Stool losses of phosphate are minor, ie, 100-300 mg/d from sloughed intestinal cells and gastrointestinal secretions. However, these losses can be increased dramatically in persons with diseases that cause severe diarrhea or intestinal malabsorption.

Bone loses approximately 300 mg of phosphate per day, but that is generally balanced by an uptake of 300 mg. Bone metabolism of phosphate is influenced by factors that determine bone formation and destruction, ie, PTH, vitamin D, sex hormones, acid-base balance, and generalized inflammation.

The excess ingested phosphate is excreted by the kidneys to maintain phosphate balance. Major sites of regulation of phosphate excretion are the early proximal renal tubule and the distal convoluted tubule. In the proximal tubule, phosphate reabsorption by type 2 sodium phosphate cotransporters is regulated by dietary phosphate, PTH, and vitamin D. High dietary phosphate intake and elevated PTH levels decrease proximal renal tubule phosphate absorption, thus enhancing renal excretion.

Conversely, low dietary phosphate intake, low PTH levels, and high vitamin D levels enhance renal proximal tubule phosphate absorption. To some extent, phosphate regulates its own regulators. High phosphate concentrations in the blood down-regulate the expression of some phosphate transporters, decrease vitamin D production, and increase PTH secretion by the parathyroid gland. Distal tubule phosphate handling is less well understood. PTH increases phosphate absorption in the distal tubule, but the mechanisms by which this occurs are unknown. Renal phosphate excretion can also be increased by the administration of loop diuretics.

PTH and vitamin D were previously the only recognized regulators of phosphate metabolism. However, several novel regulators of mineral homeostasis have been identified through studies of serum factors associated with phosphate wasting syndromes such as oncogenic osteomalacia and the hereditary forms of hypophosphatemic rickets, have been discovered.

The first to be discovered was a phosphate-regulating gene with homologies to endopeptidases on the X chromosome (PHEX), a neutral endopeptidase mutated in the syndrome of X-linked hypophosphatemic rickets. The characteristics of this syndrome (ie, hypophosphatemia, renal phosphate wasting, low 1,25-dihydroxyvitamin D levels) and the fact that PHEX was identified as an endopeptidase suggested the possibility that PHEX might be responsible for the catabolism of a non-PTH circulating factor that regulated proximal tubule phosphate transport and vitamin D metabolism. A potential substrate for PHEX was subsequently identified as fibroblast growth factor 23 (FGF23).

Several lines of evidence support a phosphaturic role for FGF23. Another syndrome of hereditary hypophosphatemic rickets, autosomal dominant hypophosphatemic rickets, is characterized by a mutation in the FGF23 gene that renders the protein resistant to proteolytic cleavage and, thus, presumably more available for inhibition of renal phosphate transport. Administration of recombinant FGF23 produces phosphaturia, and FGF23 knockout mice exhibit hyperphosphatemia.

The syndrome of oncogenic osteomalacia, characterized by acquired hypophosphatemic rickets and renal phosphate wasting in association with specific tumors, is associated with overexpression of FGF23. Interestingly, in this syndrome, overexpression of FGF23 is accompanied by 2 other phosphaturic agents, matrix extracellular phosphoglycoprotein (MEPE) and frizzled related protein-4. The roles of these 2 latter proteins and their relationship with FGF23 and PHEX are unknown.

The physiologic role of FGF23 in the regulation of phosphate homeostasis is still under investigation. FGF23 is produced in several types of tissue, including heart, liver, thyroid/parathyroid, small intestine, and bone tissue. The source of circulating FGF23 has not been conclusively established; however, the highest mRNA expression for FGF23 in mice is in bone.[9, 10] FGF23 production by osteoblasts is stimulated by 1,25 vitamin D.[9] Conversely, individuals with X-linked hypophosphatemic rickets show inappropriately depressed levels of 1,25 vitamin D due to FGF23-mediated suppression of 1-alpha hydroxylase activity.

Studies in patients with end-stage renal disease found that FGF23 levels rose with decreasing creatinine clearance rates and increasing plasma phosphorus levels. Klotho, a transmembrane protein, is an essential cofactor for the effects of FGF23 on renal proximal tubule cells.[11] Inactivation or deletion of Klotho expression results in hyperphosphatemia and accelerated aging. The relationship between these 2 functions of Klotho remains unknown.

A study also demonstrated that FGF23 levels rapidly decreased after kidney transplantation suggesting that FGF23 is cleared by the kidney.[12] Thus, residual FGF23 could contribute to the hypophosphatemia frequently seen in posttransplant patients. In healthy young men without renal disease, phosphate intake did not significantly increase FGF23 levels, suggesting that FGF23 may not play a role in acute phosphate homeostasis.[13]

One other family of phosphate-regulating factors is the stanniocalcins (STC1 and STC2). In fish, where it was first described, STC1 inhibits calcium entry into the organism through the gills and intestines. However, in mammals, STC1 stimulates phosphate reabsorption in the small intestine and renal proximal tubules and STC2 inhibits the promoter activity of the type 2 sodium phosphate cotransporter, while the effects on calcium homeostasis are of lesser magnitude. Very little is known about the clinical significance of these newly described mineral-regulating agents or about potential interactions with either the PTH-vitamin D axis or with the phosphatonin-PHEX system.


Any of 3 pathogenic mechanisms can cause hypophosphatemia.

Inadequate intake

Inadequate phosphate intake alone is an uncommon cause of hypophosphatemia. The ease of intestinal absorption of phosphate coupled with the ubiquitous presence of phosphate in almost all ingested food substances ensures that daily phosphate requirements are more than met by even a less-than-ideal diet.

Hypophosphatemia is most often caused by long-term, relatively low phosphate intake in the setting of a sudden increase in intracellular phosphate requirements such as occurs with refeeding. Intestinal malabsorption can contribute to inadequate phosphate intake, especially if coupled with a poor diet. Although generally not essential for adequate phosphate absorption, vitamin D deficiency can contribute to hypophosphatemia by failing to stimulate phosphate absorption in cases of poor dietary ingestion. Case reports also document patients developing hypophosphatemia due to excessive use of antacids, particularly calcium-, magnesium-, or aluminum-containing antacids.

Increased excretion

Increased excretion of phosphate is a more common mechanism for the development of hypophosphatemia. The most common cause of increased renal phosphate excretion is hyperparathyroidism due to the ability of PTH to inhibit proximal renal tubule phosphate transport. However, frank hypophosphatemia is not universal and is most often mild.

Increased excretion of phosphate can also be induced by forced saline diuresis due to the inhibitory effect of saline diuresis on all proximal renal tubule transport processes. Again, the degree of hypophosphatemia is generally minimal. Vitamin D deficiency not only impairs intestinal absorption, but also decreases renal absorption of phosphate. Several genetic and acquired syndromes of phosphate wasting and associated skeletal abnormalities have been described.

Shift from extracellular to intracellular space

This pathogenetic mechanism alone is an uncommon cause of hypophosphatemia, but it can exacerbate hypophosphatemia produced by other mechanisms. Clinical situations in which this mechanism is the major cause of hypophosphatemia are the treatment of diabetic ketoacidosis, refeeding, short-term increases in cellular demand (eg, hungry bones syndrome), and acute respiratory alkalosis.



United States

Exact figures are difficult to determine, mainly because phosphate measurements are often not obtained with routine laboratory studies and are determined only when the care provider has a high index of suspicion for hypophosphatemia. In the general population of hospitalized patients, hypophosphatemia is observed in 1-5% of individuals and is usually mild and asymptomatic. The percentage rises steeply in patients with alcoholism, diabetic ketoacidosis, or sepsis, in whom studies have reported frequency rates of up to 40-80%.

Hypophosphatemia has been reported in a significant number of patients following partial hepatectomy for transplantation (up to 55%) and in acute hepatic failure, attributed to an increase in cell utilization due to regeneration of liver tissue. Hypophosphatemia in this setting is associated with a favorable prognosis. Hypophosphatemia is also seen in approximately one third of hematopoietic cell transplantation, but, in this setting, it correlates highly with mortality.

Hypophosphatemia occurs in a significant percentage of kidney transplant recipients (50-80%), in particular immediately after transplantation. In many patients it can persist for the life of the transplant. Hypophosphatemia has also been reported in association with the metabolic syndrome.


The morbidity of hypophosphatemia is highly dependent on cause, duration, and severity.


Hypophosphatemia has no race predilection except for the syndrome of X-linked hypophosphatemic rickets, which predominates in Caucasian populations.


Hypophosphatemia has no sex predilection except for the syndrome of X-linked hypophosphatemic rickets, which is seen in male children.


Hypophosphatemia can occur in persons of any age. Acquired hypophosphatemia tends to occur in late adolescence to adulthood. Cases occurring in late adolescence are often related to eating disorders. With aging, hypophosphatemia is often related to alcoholism, tumors, malabsorption, or vitamin D deficiency.


Most patients with hypophosphatemia are asymptomatic. History alone rarely alerts the physician to the possibility of hypophosphatemia. In cases of oncogenic osteomalacia or in some of the genetic causes of phosphate wasting, patients complain of bone pain and fractures. Otherwise, physicians must have a high index of suspicion and must be aware of the clinical conditions that might be complicated by hypophosphatemia.[14]

Symptoms of hypophosphatemia are nonspecific and highly dependent on cause, duration, and severity.


No physical signs are specific for hypophosphatemia. In fact, physical signs of mild hypophosphatemia are generally absent.


The differential diagnosis of hypophosphatemia is most easily considered according to pathogenetic mechanisms. The following discussion conforms to this approach, but note that hypophosphatemia is frequently the result of more than one mechanism.

Laboratory Studies

Imaging Studies


Histologic Findings

Most parathyroid lesions are adenomas. Occasionally, a carcinoma is found. Most of the tumors causing oncogenic osteomalacia are benign (eg, hemangiopericytoma).

Medical Care

Medical care is highly dependent on 3 factors: cause, severity, and duration. Phosphate distribution varies among patients, so no formulas reliably determine the magnitude of the phosphate deficit. The average patient requires 1000-2000 mg (32-64 mmol) of phosphate per day for 7-10 days to replenish the body stores.

Surgical Care

Patients with primary hyperparathyroidism benefit from parathyroidectomy. For patients in whom parathyroidectomy is not feasible, treatment with the new calcium mimetic agents has shown demonstrable control of hyperparathyroidism. Patients with oncogenic osteomalacia are cured by excision of the tumor causing the phosphate wasting and relative vitamin D deficiency.



A regular diet generally provides all of the phosphate required for the day and more. For patients with phosphate wasting, high-phosphate diets (including dairy products, meats, and beans) should be encouraged, along with phosphate supplements. Cow’s milk, an excellent and accessible source of phosphate, contains 1 mg (0.032 mmol) of elemental phosphate per milliliter. Consumption of vitamin D–supplemented foods should also be encouraged.


For transient mild hypophosphatemia, no activity restrictions are necessary. For chronic phosphate wasting syndromes, the degree of bone disease is the best guide for assessing activity. Severe osteomalacia puts patients at high risk for fracture. Notably, these patients often have accompanying proximal muscle weakness and muscle pain that in and of themselves restrict activity. These patients with established osteomalacia should avoid high-impact activities and should practice fall precautions.

Medication Summary

The goals of pharmacotherapy are to increase serum phosphate levels, to reduce morbidity, and to prevent complications.

Potassium acid phosphate (Neutra-Phos-K)

Clinical Context:  PO preparations are available as sodium or potassium phosphate in cap or liquid form. Neutra-Phos packets contain 250 mg of phosphorus/packet. Tabs contain 250, 125.6, or 114 mg apiece. Liquid preparations are available as 250 mg/75 mL.

Potassium phosphates, IV

Clinical Context:  Contains 3 mmol/mL of phosphorus and 4.4 mEq/mL of potassium.

Sodium phosphates, IV

Clinical Context:  Contains 3 mmol/mL of phosphorus and 4 mEq/mL of sodium.

Class Summary

Phosphate salts are used to increase serum phosphate levels. Phosphorus is involved in many biochemical functions in the body and significant metabolic and enzyme reactions in almost all organs and tissues; it exerts a modifying influence on the steady state of calcium levels, a buffering effect on acid-base equilibrium, and a primary role in the renal excretion of hydrogen ion. For severe hypophosphatemia (< 1 mg/dL), use parenteral preparations of phosphate for repletion. IV preparations are available as sodium or potassium phosphate. Response to IV serum phosphorus supplementation is highly variable and can be associated with hyperphosphatemia and hypocalcemia. Infusion rate and choice of initial dosage is based on severity of hypophosphatemia and presence of symptoms. Closely monitor serum phosphate and calcium levels. For less severe hypophosphatemia (1-2 mg/dL), PO phosphate salt preparations can be used.

Ergocalciferol (vitamin D-2)

Clinical Context:  Requires conversion to active 1,25 dihydroxy cholecalciferol in kidneys. Administered PO.

Calcitriol (Calcijex, Rocaltrol)

Clinical Context:  Active form of vitamin D, 1,25 dihydroxyvitamin D-3. Use in patients with renal failure who are unable to convert inactive prohormone forms to active metabolite. Available in PO and parenteral form.

Doxercalciferol (Hectorol)

Clinical Context:  Requires hydroxylation in liver to be converted to an active vitamin D metabolite. May cause less toxicity than calcitriol with regard to calcium homeostasis. Predominantly used to treat secondary hyperparathyroidism of renal failure

Paricalcitol (Zemplar)

Clinical Context:  Vitamin D-3 analogue available in parenteral form and predominantly used to treat secondary hyperparathyroidism of renal failure, especially when calcitriol treatment has resulted in hypercalcemia. Appears to have a lesser effect on calcium and phosphorus metabolism than calcitriol. For this reason, it is not as useful as calcitriol for the treatment of hypophosphatemia.

Class Summary

Vitamin D enhances intestinal and renal absorption of phosphate. Can be administered in addition to phosphate supplements to increase serum phosphate and total body phosphate stores.

Cinacalcet (Sensipar)

Clinical Context:  This drug is available in oral form and has to be taken daily for desired effect. To monitor efficacy, the drug should be taken at the same time every day and the intact parathyroid hormone (iPTH) level should also be taken at the same time every time it is checked. The clinician needs to monitor also for the development of hypocalcemia.

Class Summary

This category of drug activates the calcium sensing receptor on parathyroid gland cells, thus diminishing the release of parathyroid hormone. These agents are useful for the control of hyperparathyroidism in patients who are unwilling to undergo surgery or who are suboptimal candidates for surgery.

Further Inpatient Care

Further Outpatient Care

Inpatient & Outpatient Medications






Eleanor Lederer, MD, Professor of Medicine, Chief, Nephrology Division, Director, Nephrology Training Program, Director, Metabolic Stone Clinic, Kidney Disease Program, University of Louisville School of Medicine; Consulting Staff, Louisville Veterans Affairs Hospital

Disclosure: Dept of Veterans Affairs Grant/research funds Research


Rosemary Ouseph, MD, Professor of Medicine, Director of Kidney Transplant, University of Louisville School of Medicine

Disclosure: Nothing to disclose.

Snehal Patel, MD, Fellow, Department of Nephrology, University of Louisville School of Medicine

Disclosure: Nothing to disclose.

Specialty Editors

James W Lohr, MD, Professor, Department of Internal Medicine, Division of Nephrology, Fellowship Program Director, University of Buffalo State University of New York School of Medicine and Biomedical Sciences

Disclosure: Alexion Salary Employment

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Christie P Thomas, MBBS, FRCP, FASN, FAHA, Professor, Department of Internal Medicine, Division of Nephrology, Medical Director, Kidney and Kidney/Pancreas Transplant Program, University of Iowa Hospitals and Clinics

Disclosure: Nothing to disclose.

Rebecca J Schmidt, DO, FACP, FASN, Professor of Medicine, Section Chief, Department of Medicine, Section of Nephrology, West Virginia University School of Medicine

Disclosure: Renal Ventures Ownership interest Other

Chief Editor

Vecihi Batuman, MD, FACP, FASN, Professor of Medicine, Section of Nephrology-Hypertension, Tulane University School of Medicine; Chief, Medicine Service, Southeast Louisiana Veterans Health Care System

Disclosure: Nothing to disclose.

Additional Contributors

We wish to thank Deepak Mittal, MD, and Datinder Deo, MD, for their previous contributions to this article.


  1. Lapointe JY, Tessier J, Paquette Y, Wallendorff B, Coady MJ, Pichette V. NPT2a gene variation in calcium nephrolithiasis with renal phosphate leak. Kidney Int. Jun 2006;69(12):2261-7. [View Abstract]
  2. Prié D, Huart V, Bakouh N, Planelles G, Dellis O, Gérard B, et al. Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. N Engl J Med. 2002;347:983-991. [View Abstract]
  3. Jones A, Tzenova J, Frappier D, et al. Hereditary hypophosphatemic rickets with hypercalciuria is not caused by mutations in the Na/Pi cotransporter NPT2 gene. J Am Soc Nephrol. Mar 2001;12(3):507-14. [View Abstract]
  4. Segawa H, Onitsuka A, Kuwahata M, Hanabusa E, Furutani J, Kaneko I, et al. Type IIc sodium-dependent phosphate transporter regulates calcium metabolism. J Am Soc Nephrol. 2009;20:104-113. [View Abstract]
  5. Nowik M, Picard N, Stange G, Capuano P, Tenenhouse HS, Biber J, et al. Renal phosphaturia during metabolic acidosis revisited: molecular mechanisms for decreased renal phosphate reabsorption. Pflugers Arch. 2008;457:539-549. [View Abstract]
  6. Collins JF, Bal L, Ghishan FK. The SLC20 family of protiens: dual functions as sodium-phosphate cotransporters and viral receptors. Pflugers Arch. 2004;447:647-652. [View Abstract]
  7. Virkki LV, Biber J, Murer H, Forster IC. Phosphate transporters: a tale of two solute carrier families. Am J Physiol Renal Physiol. 2007;293:F643-654. [View Abstract]
  8. Shaikh A, Berndt T, Kumar R. Regulation of phosphate homeostasis by the phosphatonins and other novel mediators. Pediatr Nephrol. Aug 2008;23(8):1203-10. [View Abstract]
  9. Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab. Jul 2006;291(1):E38-49. [View Abstract]
  10. Mirams M, Robinson BG, Mason RS, Nelson AE. Bone as a source of FGF23: regulation by phosphate?. Bone. Nov 2004;35(5):1192-9. [View Abstract]
  11. Razzaque MS. FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player?. Am J Physiol Renal Physiol. 2009;296:F70-476. [View Abstract]
  12. Pande S, Ritter CS, Rothstein M, Wiesen K, Vassiliadis J, Kumar R. FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol. 2006;104(1):p23-32. [View Abstract]
  13. Nishida Y, Taketani Y, Yamanaka-Okumura H, Imamura F, Taniguchi A, Sato T. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int. Dec 2006;70(12):2141-7. [View Abstract]
  14. Assadi F. Hypophosphatemia: an evidence-based problem-solving approach to clinical cases. Iran J Kidney Dis. Jul 2010;4(3):195-201. [View Abstract]
  15. Schubert L, DeLuca HF. Hypophosphatemia is responsible for skeletal muscle weakness of vitamin D deficiency. Arch Biochem Biophys. Aug 15 2010;500(2):157-61. [View Abstract]
  16. O'Connor LR, Wheeler WS, Bethune JE. Effect of hypophosphatemia on myocardial performance in man. N Engl J Med. Oct 27 1977;297(17):901-3. [View Abstract]
  17. Clarke BL, Wynne AG, Wilson DM, Fitzpatrick LA. Osteomalacia associated with adult Fanconi's syndrome: clinical and diagnostic features. Clin Endocrinol (Oxf). Oct 1995;43(4):479-90. [View Abstract]
  18. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest. Sep 2003;112(5):683-92. [View Abstract]
  19. Kreisl TN, Kimn L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent Bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurent glioblastoma. J Clin Oncol. 2009;27:740-745. [View Abstract]
  20. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, et al. Effricacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008;26:4311-4318. [View Abstract]
  21. Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med. May 11 2006;354(19):2006-13. [View Abstract]
  22. Joensuu H, Reichardt P. Imatinib and altered bone and mineral metabolism. N Engl J Med. Aug 10 2006;355(6):628; author reply 628-9. [View Abstract]
  23. Gollob JA, Rathmell WK, Richmond TM, Marino CB, Miller EK, Grigson G, et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients wtih metastatic renal cell cancer. J Clin Oncol. 2007;25:3288-3295. [View Abstract]
  24. Micetich KC, Futscher B, Koch D, Fisher RI, Erickson LC. Phase I study of streptozocin- and carmustine-sequenced administration in patients with advanced cancer. J Natl Cancer Inst. 1992;84:256-260. [View Abstract]
  25. Stöhr W, Paulides M, Bielack S, Jürgens H, Treuner J, Rossi R, et al. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System. Pediatr Blood Cancer. 2007;48:447-452. [View Abstract]
  26. Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf. 2001;24:19-38. [View Abstract]
  27. Paleologos M, Stone E, Braude S. Persistent, progressive hypophosphataemia after voluntary hyperventilation. Clin Sci (Lond). May 2000;98(5):619-25. [View Abstract]
  28. Ambuhl PM, Meier D, Wolf B, et al. Metabolic aspects of phosphate replacement therapy for hypophosphatemia after renal transplantation: impact on muscular phosphate content, mineral metabolism, and acid/base homeostasis. Am J Kidney Dis. Nov 1999;34(5):875-83. [View Abstract]
  29. Aubier M, Murciano D, Lecocguic Y, et al. Effect of hypophosphatemia on diaphragmatic contractility in patients with acute respiratory failure. N Engl J Med. Aug 15 1985;313(7):420-4. [View Abstract]
  30. Barak V, Schwartz A, Kalickman I, et al. Prevalence of hypophosphatemia in sepsis and infection: the role of cytokines. Am J Med. Jan 1998;104(1):40-7. [View Abstract]
  31. Basquerizo A, Anselmo D, Shackleton C, et al. Phosphorus as an early predictive factor in patients with acute liver failure. Transplantation. 75:2007-2014. [View Abstract]
  32. Betro MG, Pain RW. Hypophosphataemia and hyperphosphataemia in a hospital population. Br Med J. Jan 29 1972;1(795):273-6. [View Abstract]
  33. Bollaert PE, Levy B, Nace L, et al. Hemodynamic and metabolic effects of rapid correction of hypophosphatemia in patients with septic shock. Chest. Jun 1995;107(6):1698-701. [View Abstract]
  34. Bowe AE, Finnegan R, Jan de Beur SM, et al. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun. Jun 22 2001;284(4):977-81. [View Abstract]
  35. Camp MA, Allon M. Severe hypophosphatemia in hospitalized patients. Miner Electrolyte Metab. 1990;16(6):365-8. [View Abstract]
  36. Chung PY, Sitrin MD, Te HS. Serum phosphorus levels predict clinical outcome in fulminant hepatic failure. Liver Transplantation. 2003;9:248-253. [View Abstract]
  37. Cohen J, Kogan A, Sahar G, et al. Hypophosphatemia following open heart surgery: incidence and consequences. Eur J Cardiothorac Surg. 26:306-310. [View Abstract]
  38. Craddock PR, Yawata Y, VanSanten L, et al. Acquired phagocyte dysfunction. A complication of the hypophosphatemia of parenteral hyperalimentation. N Engl J Med. Jun 20 1974;290(25):1403-7. [View Abstract]
  39. Crook M. Hypophosphataemia in a hospital population and the incidence of concomitant hypokalaemia. Ann Clin Biochem. Jan 1992;29 ( Pt 1):64-6. [View Abstract]
  40. Crook MA, Hally V, Panteli JV. The importance of the refeeding syndrome. Nutrition. Jul-Aug 2001;17(7-8):632-7. [View Abstract]
  41. Daily WH, Tonnesen AS, Allen SJ. Hypophosphatemia--incidence, etiology, and prevention in the trauma patient. Crit Care Med. Nov 1990;18(11):1210-4. [View Abstract]
  42. DeFronzo RA, Lang R. Hypophosphatemia and glucose intolerance: evidence for tissue insensitivity to insulin. N Engl J Med. Nov 27 1980;303(22):1259-63. [View Abstract]
  43. Dickerson RN, Gervasio JM, Sherman JJ, et al. A comparison of renal phosphorus regulation in thermally injured and multiple trauma patients receiving specialized nutrition support. JPEN J Parenter Enteral Nutr. May-Jun 2001;25(3):152-9. [View Abstract]
  44. DiMeglio LA, Econs MJ. Hypophosphatemic rickets. Rev Endocr Metab Disord. Apr 2001;2(2):165-73. [View Abstract]
  45. DiMeglio LA, White KE, Econs MJ. Disorders of phosphate metabolism. Endocrinol Metab Clin North Am. Sep 2000;29(3):591-609. [View Abstract]
  46. Drezner MK. PHEX gene and hypophosphatemia. Kidney Int. Jan 2000;57(1):9-18. [View Abstract]
  47. Drezner MK. Tumor-induced osteomalacia. Rev Endocr Metab Disord. 2001;2:175-86. [View Abstract]
  48. Duerksen DR, Papineau N. Electrolyte abnormalities in patients with chronic renal failure receiving parenteral nutrition. JPEN J Parenter Enteral Nutr. Mar-Apr 1998;22(2):102-4. [View Abstract]
  49. Econs MJ. New insights into the pathogenesis of inherited phosphate wasting disorders. Bone. Jul 1999;25(1):131-5. [View Abstract]
  50. Faintuch J, Soriano FG, Ladeira JP, et al. Refeeding procedures after 43 days of total fasting. Nutrition. Feb 2001;17(2):100-4. [View Abstract]
  51. Gannage MH, Abikaram G, Nasr F, Awada H. Osteomalacia secondary to celiac disease, primary hyperparathyroidism, and Graves' disease. Am J Med Sci. Feb 1998;315(2):136-9. [View Abstract]
  52. Green J, Debby H, Lederer E, et al. Evidence for a PTH-independent humoral mechanism in post-transplant hypophosphatemia and phosphaturia. Kidney Int. Sep 2001;60(3):1182-96. [View Abstract]
  53. Guy JM, Stewart MF, Olukoga A, et al. Hypophosphataemia in general practice patients. Ann Clin Biochem. Jan 1999;36 ( Pt 1):37-42. [View Abstract]
  54. Haglin L. Hypophosphataemia in anorexia nervosa. Postgrad Med J. May 2001;77(907):305-11. [View Abstract]
  55. Haglin L, Burman LA, Nilsson M. High prevalence of hypophosphataemia amongst patients with infectious diseases. A retrospective study. J Intern Med. Jul 1999;246(1):45-52. [View Abstract]
  56. Hardy DC, Murphy WA, Siegel BA, et al. X-linked hypophosphatemia in adults: prevalence of skeletal radiographic and scintigraphic features. Radiology. May 1989;171(2):403-14. [View Abstract]
  57. Hicks W, Hardy G. Phosphate supplementation for hypophosphataemia and parenteral nutrition. Curr Opin Clin Nutr Metab Care. May 2001;4(3):227-33. [View Abstract]
  58. Jaureguiberry G, Carpenter TO, Forman S, Jüppner H, Bergwitz C. A novel missense mutation in SLC34A3 that causes hereditary hypophosphatemic rickets with hypercalciuria in humans identifies threonine 137 as an important determinant of sodium-phosphate cotransport in NaPi-IIc. Am J Physiol Renal Physiol. 2008;295:F371-379. [View Abstract]
  59. Julian BA, Quarles LD, Niemann KM. Musculoskeletal complications after renal transplantation: pathogenesis and treatment. Am J Kidney Dis. Feb 1992;19(2):99-120. [View Abstract]
  60. Kagansky N, Levy S, Koren-Morag N. Hypophosphataemia in old patients is associated with the refeeding syndrome and reduced survival. J Intern Med. 2005;257:461-468. [View Abstract]
  61. Kalaitzidis R, Tsimihodimos V, Bairaktari E, et al. Disturbances of phosphate metabolism: another feature of metabolic syndrome. Am J Kidney Dis. 45:851-8. [View Abstract]
  62. Khardori R. Refeeding syndrome and hypophosphatemia. J Intensive Care Med. 2005;20:174-5. [View Abstract]
  63. Kohn MR, Golden NH, Shenker IR. Cardiac arrest and delirium: presentations of the refeeding syndrome in severely malnourished adolescents with anorexia nervosa. J Adolesc Health. Mar 1998;22(3):239-43. [View Abstract]
  64. Kraft MD, Btaiche IF, Sacks GS, Kudsk KA. Treatment of electrolyte disorders in adult patients in the intensive care unit. Am J Health Syst Pharm. 62:1663-82. [View Abstract]
  65. Kumar R. Tumor-induced osteomalacia and the regulation of phosphate homeostasis. Bone. Sep 2000;27(3):333-8. [View Abstract]
  66. Laaban JP, Grateau G, Psychoyos I, et al. Hypophosphatemia induced by mechanical ventilation in patients with chronic obstructive pulmonary disease. Crit Care Med. Nov 1989;17(11):1115-20. [View Abstract]
  67. Laaban JP, Waked M, Laromiguiere M, et al. Hypophosphatemia complicating management of acute severe asthma. Ann Intern Med. Jan 1 1990;112(1):68-9. [View Abstract]
  68. Lacy MQ, Gertz MA. Acquired Fanconi's syndrome associated with monoclonal gammopathies. Hematol Oncol Clin North Am. Dec 1999;13(6):1273-80. [View Abstract]
  69. Larsson L, Rebel K, Sorbo B. Severe hypophosphatemia--a hospital survey. Acta Med Scand. 1983;214(3):221-3. [View Abstract]
  70. Lee JH, Choi SJ, Lee JH, et al. Severe metabolic abnormalities after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 35:63-69. [View Abstract]
  71. Levi M. Novel NaPi-2c mutations that cause mistargeting of NaPi-2c protien and uncoupling of Na-Pi cause HHRH. Am J Physiol Renal Physiol. 2008;295:F369-370. [View Abstract]
  72. Lichtman MA, Miller DR, Cohen J, Waterhouse C. Reduced red cell glycolysis, 2, 3-diphosphoglycerate and adenosine triphosphate concentration, and increased hemoglobin-oxygen affinity caused by hypophosphatemia. Ann Intern Med. Apr 1971;74(4):562-8. [View Abstract]
  73. Liu YL, Lin HH, Yu CC, Kuo HL, Yang YF, Chou CY. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients. Ren Fail. 2006;28(8):701-7. [View Abstract]
  74. Machiels JP, Dive A, Donckier J, Installe E. Reversible myocardial dysfunction in a patient with alcoholic ketoacidosis: a role for hypophosphatemia. Am J Emerg Med. Jul 1998;16(4):371-3. [View Abstract]
  75. Malloy PJ, Pike JW, Feldman D. The vitamin D receptor and the syndrome of hereditary 1,25- dihydroxyvitamin D-resistant rickets. Endocr Rev. Apr 1999;20(2):156-88. [View Abstract]
  76. Marinella MA. Refeeding syndrome and hypophosphatemia. J Intensive Care Med. 2005;20:155-159. [View Abstract]
  77. Marshall MR, Golper TA, Shaver MJ, et al. Sustained low-efficiency dialysis for critically ill patients requiring renal replacement therapy. Kidney Int. 60:777-785. [View Abstract]
  78. Melvin JD, Watts RG. Severe hypophosphatemia: a rare cause of intravascular hemolysis. Am J Hematol. Mar 2002;69(3):223-4. [View Abstract]
  79. Milionis HJ, Alexandrides GE, Liberopoulos E, et al. Hypomagnesemia and concurrent acid-base and electrolyte abnormalities in patients with congestive heart failure. Eur J Heart Fail. Mar 2002;4(2):167-73. [View Abstract]
  80. Miller DW, Slovis CM. Hypophosphatemia in the emergency department therapeutics. Am J Emerg Med. Jul 2000;18(4):457-61. [View Abstract]
  81. Morris AA, Baudouin SV, Snow MH. Renal tubular acidosis and hypophosphataemia after treatment with nucleoside reverse transcriptase inhibitors. AIDS. Jan 5 2001;15(1):140-1. [View Abstract]
  82. Newman JH, Neff TA, Ziporin P. Acute respiratory failure associated with hypophosphatemia. N Engl J Med. May 12 1977;296(19):1101-3. [View Abstract]
  83. Ornstein RM, Golden NH, Jacobson MS, Shenker IR. Hypophosphatemia during nutritional rehabilitation in anorexia nervosa: implications for refeeding and monitoring. J Adolesc Health. 32:83-88. [View Abstract]
  84. Peacock M, Bilezekian JP, Klassen PS, et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 90:135-141. [View Abstract]
  85. Perreault MM, Ostrop NJ, Tierney MG, et al. Efficacy and safety of intravenous phosphate replacement in critically ill patients. Ann Pharmacother. 31(6):683-8. [View Abstract]
  86. Polderman KH, Bloemers FW, Peerdeman SM, Girbes AR. Hypomagnesemia and hypophosphatemia at admission in patients with severe head injury. Crit Care Med. Jun 2000;28(6):2022-5. [View Abstract]
  87. Pomposelli JJ, Pomfret EA, Burns DL, et al. Life-threatening hypophosphatemia after right hepatic lobectomy for live donor adult liver transplantation. Liver Transpl. Jul 2001;7(7):637-42. [View Abstract]
  88. Prie D, Beck L, Urena P, Friedlander G. Recent findings in phosphate homeostasis. Curr Opin Nephrol Hypertens. Jul 2005;14(4):318-24. [View Abstract]
  89. Prie D, Blanchet FB, Essig M, et al. Dipyridamole decreases renal phosphate leak and augments serum phosphorus in patients with low renal phosphate threshold. J Am Soc Nephrol. Jul 1998;9(7):1264-9. [View Abstract]
  90. Quarles LD, Drezner MK. Pathophysiology of X-linked hypophosphatemia, tumor-induced osteomalacia, and autosomal dominant hypophosphatemia: a perPHEXing problem. J Clin Endocrinol Metab. Feb 2001;86(2):494-6. [View Abstract]
  91. Raanani P, Levi I, Holzman F, et al. Engraftment-associated hypophosphatemia -- the role of cytokine release and steep leukocyte rise post stem cell transplantation. Bone Marrow Transplantation. 2001;27:311-317. [View Abstract]
  92. Reid IR, Hardy DC, Murphy WA, et al. X-linked hypophosphatemia: a clinical, biochemical, and histopathologic assessment of morbidity in adults. Medicine (Baltimore). Nov 1989;68(6):336-52. [View Abstract]
  93. Rubin MF, Narins RG. Hypophosphatemia: pathophysiological and practical aspects of its therapy. Semin Nephrol. Nov 1990;10(6):536-45. [View Abstract]
  94. Sankaran RT, Mattana J, Pollack S, et al. Laboratory abnormalities in patients with bacterial pneumonia. Chest. Mar 1997;111(3):595-600. [View Abstract]
  95. Schmitt CP, Mehls O. The enigma of hyperparathyroidism in hypophosphatemic rickets. Pediatr Nephrol. 2004;19:473-477. [View Abstract]
  96. Seifi S, Pezeshki ML, Khatami MR, et al. Post-renal transplantation hypophosphatemia. Transplant Proc. 35:2645-6. [View Abstract]
  97. Seikaly MG, Baum M. Thiazide diuretics arrest the progression of nephrocalcinosis in children with X-linked hypophosphatemia. Pediatrics. Jul 2001;108(1):E6. [View Abstract]
  98. Siddiqui MF, Bertorini TE. Hypophosphatemia-induced neuropathy: clinical and electrophysiologic findings. Muscle Nerve. May 1998;21(5):650-2. [View Abstract]
  99. Smyrniotis V, Kostopanagiotou G, Katsarelias D, et al. Changes of serum phosphorus levels in hepatic resections and implications on patients' outcomes. Int Surg. 88:100-4. [View Abstract]
  100. Steiner M, Steiner B, Wilhelm S, et al. Severe hypophosphatemia during hematopoietic reconstitution after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. May 2000;25(9):1015-6. [View Abstract]
  101. Strewler GJ. FGF23, hypophosphatemia, and rickets: has phosphatonin been found?. Proc Natl Acad Sci U S A. May 22 2001;98(11):5945-6. [View Abstract]
  102. Subramanian R, Khardori R. Severe hypophosphatemia. Pathophysiologic implications, clinical presentations, and treatment. Medicine (Baltimore). Jan 2000;79(1):1-8. [View Abstract]
  103. Tan HP, Madeb R, Kovach SJ, et al. Hypophosphatemia after 95 right-lobe living-donor hepatectomies for liver transplantation is not a significant source of morbidity. Transplantation. 76:1085-8. [View Abstract]
  104. Vanneste J, Hage J. Acute severe hypophosphataemia mimicking Wernicke's encephalopathy. Lancet. Jan 4 1986;1(8471):44. [View Abstract]
  105. Vaszar LT, Culpepper-Morgan JA, Winter SM. Refeeding syndrome induced by cautious enteral alimentation of a moderately malnourished patient. Gastroenterologist. Mar 1998;6(1):79-81. [View Abstract]
  106. Vered Z, Battler A, Motro M, et al. Left ventricular function in patients with chronic hypophosphatemia. Am Heart J. Apr 1984;107(4):796-8. [View Abstract]
  107. Weintraub ME. Hypophosphatemis mimicking acute Guillanin-Barre-Strohl syndrome. A complication of parenteral hyperalimentation. JAMA. Mar 8 1976;235(10):1040-1. [View Abstract]
  108. Weintraub MI, Chakravorty HP. Nutrient deficiencies after intensive parenteral alimentation. N Engl J Med. 1974;291:799.
  109. Weisinger JR, Bellorin-Font E. Magnesium and phosphorus. Lancet. Aug 1 1998;352(9125):391-6. [View Abstract]
  110. Wilson HK, Keuer SP, Lea AS, et al. Phosphate therapy in diabetic ketoacidosis. Arch Intern Med. Mar 1982;142(3):517-20. [View Abstract]
  111. Yeung SJ, McCutcheon IE, Schultz P, Gagel RF. Use of long-term intravenous phosphate infusion in the palliative treatment of tumor-induced osteomalacia. J Clin Endocrinol Metab. Feb 2000;85(2):549-55. [View Abstract]
  112. Yu X, White KE. FGF23 and disorders of phosphate homeostasis. Cytokine Growth Factor Rev. 2005;16:221-232. [View Abstract]
  113. Zazzo JF, Troche G, Ruel P, Maintenant J. High incidence of hypophosphatemia in surgical intensive care patients: efficacy of phosphorus therapy on myocardial function. Intensive Care Med. Oct 1995;21(10):826-31. [View Abstract]